{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:50:11Z","timestamp":1787028611704,"version":"build-2736575974"},"reference-count":30,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,3,29]],"date-time":"2024-03-29T00:00:00Z","timestamp":1711670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Background: This study aims to understand and describe the clinical impact of SARS-CoV-2 (COVID-19) infection in patients with Hypertrophic Cardiomyopathy (HCM). Methods: A data repository of over 6.6 million patients in a large metropolitan (Chicago IL) healthcare system was queried to identify adults with a history of HCM and COVID-19 infection between 2019 and 2021. Propensity score-matched analysis was performed based on age, sex, BMI, and elements of the cardiovascular history, including tobacco use, hypertension, hyperlipidemia, myocardial injury, and heart failure. Results: Individuals with HCM and COVID-19 infection had more total hospitalizations (41.6 v 23 per 100 persons, p &lt; 0.01), more heart-failure-related hospitalizations (24.2 v 8.7 per 100-persons, p &lt; 0.01), more non-ST elevation myocardial injury (NSTEMI) hospitalizations (8.6 v 4.6 per 100-persons, p &lt; 0.01), and increased mortality (10.8 v 5 per 100-persons, p &lt; 0.01) compared to HCM patients without a history of COVID-19 infection. Patients with HCM and COVID-19 were also noted to have a higher peak CRP when compared to those without prior COVID-19 (Inter-quartile range of 9.0\u2013106.9 v 1.8\u201321.3, p &lt; 0.01). Conclusions: In patients with HCM, COVID-19 infection is associated with increased incidence of myocardial injury, increased number of total and heart-failure specific hospitalizations, and increased mortality.<\/jats:p>","DOI":"10.3390\/jcdd11040104","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T11:11:09Z","timestamp":1712229069000},"page":"104","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Clinical Impact of SARS-CoV-2 on Hypertrophic Cardiomyopathy"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8562-7539","authenticated-orcid":false,"given":"Danish","family":"Saleh","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiying","family":"Meng","sequence":"additional","affiliation":[{"name":"Bluhm Cardiovascular Institute Clinical Trials Unit (BCVI-CTU), Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Johnson","sequence":"additional","affiliation":[{"name":"Information Technology, Research Analytics, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Baldridge","sequence":"additional","affiliation":[{"name":"Bluhm Cardiovascular Institute Clinical Trials Unit (BCVI-CTU), Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison R.","family":"Zielinski","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"Bluhm Cardiovascular Institute, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4039-8490","authenticated-orcid":false,"given":"Lubna","family":"Choudhury","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"},{"name":"Bluhm Cardiovascular Institute, Northwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,3,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical Course and Management of Hypertrophic Cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e012250","DOI":"10.1161\/JAHA.119.012250","article-title":"Prevalence of unexplained left ventricular hypertrophy by cardiac magnetic resonance imaging in MESA","volume":"8","author":"Massera","year":"2019","journal-title":"J. Am. Heart Assoc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","article-title":"New perspectives on the prevalence of hypertrophic cardiomyopathy","volume":"65","author":"Semsarian","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","unstructured":"Maron, M.S. (2023, October 05). Hypertrophic Cardiomyopathy: Clinical Manifestations, Diagnosis, and Evaluation. Uptodate. Available online: https:\/\/www.uptodate.com\/contents\/hypertrophic-cardiomyopathy-clinical-manifestations-diagnosis-and-evaluation."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"107448","DOI":"10.1016\/j.carpath.2022.107448","article-title":"Commentary on the enigma of small vessel disease in hypertrophic cardiomyopathy: Is invasive assessment of microvascular resistance a novel independent predictor of prognosis?","volume":"60","author":"Achim","year":"2022","journal-title":"Cardiovasc. Pathol."},{"key":"ref_6","first-page":"5063","article-title":"Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy","volume":"9","author":"Fang","year":"2017","journal-title":"Am. J. Transl. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1136\/heartjnl-2011-300960","article-title":"Low-grade inflammation and the phenotypic expression of myocardial fibrosis in hypertrophic cardiomyopathy","volume":"98","author":"Kuusisto","year":"2012","journal-title":"Heart"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.amjcard.2020.06.040","article-title":"Relation of late gadolinium enhancement and extracellular volume fraction to ventricular arrhythmias in hypertrophic cardiomyopathy","volume":"131","author":"Levine","year":"2020","journal-title":"Am. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1054-8807(03)00036-X","article-title":"Surgical pathology of subaortic septal myectomy associated with hypertrophic cardiomyopathy: A study of 204 cases (1996\u20132000)","volume":"12","author":"Lamke","year":"2003","journal-title":"Cardiovasc. Pathol."},{"key":"ref_10","unstructured":"Johns Hopkins Coronavirus Resource Center (2021, November 08). Available online: https:\/\/coronavirus.jhu.edu\/data."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e2126456","DOI":"10.1001\/jamanetworkopen.2021.26456","article-title":"Clinical characteristics of multisystem inflammatory syndrome in adults: A systematic review","volume":"4","author":"Patel","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4049\/jimmunol.2000413","article-title":"COVID-19 as an acute inflammatory disease","volume":"205","author":"Manjili","year":"2020","journal-title":"J. Immunol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1161\/CIRCRESAHA.123.321878","article-title":"COVID-19, myocarditis and pericarditis","volume":"132","author":"Fairweather","year":"2023","journal-title":"Circ. Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.15585\/mmwr.mm7035e5","article-title":"Association Between COVID-19 and Myocarditis Using Hospital-Based Administrative Data\u2014United States, March 2020\u2013January 2021","volume":"70","author":"Boehmer","year":"2021","journal-title":"MMWR. Morb. Mortal. Wkly. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s00392-022-02141-9","article-title":"Myocarditis mortality with and without COVID-19: Insights from a national registry","volume":"113","author":"Bemtgen","year":"2024","journal-title":"Clin. Res. Cardiol."},{"key":"ref_16","first-page":"708","article-title":"Myocyte Specific Upregulation of ACE2 in Cardiovascular Disease: Implications for SARS-CoV-2 Mediated Myocarditis","volume":"142","author":"Tucker","year":"2020","journal-title":"Circulation"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e007220","DOI":"10.1161\/CIRCHEARTFAILURE.120.007220","article-title":"Approach to acute cardiovascular complications in COVID-19 infection","volume":"13","author":"Ranard","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/ejhf.3043","article-title":"Impact of COVID\u201419 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial","volume":"25","author":"Bhatt","year":"2023","journal-title":"Eur. J. Heart Fail."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1093\/eurheartj\/ehl525","article-title":"Myocarditis in hypertrophic cardiomyopathy patients presenting acute clinical deterioration","volume":"28","author":"Frustaci","year":"2007","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"ehad655-2378","DOI":"10.1093\/eurheartj\/ehad655.2378","article-title":"Examining the effect of COVID-19 on hypertrophic cardiomyopathy hospitalizations in the USA: A nationwide propensity-score matched analysis","volume":"44","author":"Desai","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_24","unstructured":"AJMC Staff (2023, October 05). A Timeline of COVID-19 Vaccine Developments in 2021. Available online: https:\/\/www.ajmc.com\/view\/a-timeline-of-covid-19-vaccine-developments-in-2021."},{"key":"ref_25","unstructured":"(2024, January 11). Available online: https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST040222."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/ehf2.13964","article-title":"Impact of SARS-CoV-2 infection in patients with hypertrophic cardiomyopathy: Results of an international multicentre registry","volume":"9","author":"Gimeno","year":"2022","journal-title":"ESC Heart Fail."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"745790","DOI":"10.3389\/fcvm.2021.745790","article-title":"COVID-19 in Adults With Hypertrophic Cardiomyopathy","volume":"8","author":"Arabadjian","year":"2021","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1002\/ehf2.14272","article-title":"Alcohol septal ablation in hypertrophic cardiomyopathy: For which patients?","volume":"10","author":"Achim","year":"2023","journal-title":"ESC Heart Fail."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s10741-023-10303-8","article-title":"Infection as an under-recognized precipitant of acute heart failure: Prognostic and therapeutic implications","volume":"28","author":"Bezati","year":"2023","journal-title":"Heart Fail. Rev."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/4\/104\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:20:34Z","timestamp":1760106034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/4\/104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,29]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["jcdd11040104"],"URL":"https:\/\/doi.org\/10.3390\/jcdd11040104","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,29]]}}}